RHYTHM PHARMACEUTICALS, INC. Logo

RHYTHM PHARMACEUTICALS, INC.

Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.

RYTM | US

Overview

Corporate Details

ISIN(s):
US76243J1051
LEI:
Country:
United States of America
Address:
222 BERKELEY STREET, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing precision medicines for rare neuroendocrine diseases. The company focuses on treating conditions characterized by hyperphagia (insatiable hunger) and severe obesity that stem from rare genetic deficiencies. Its lead therapeutic, setmelanotide (marketed as IMCIVREE), is a precision medicine designed to address the root cause of these disorders by targeting the melanocortin-4 receptor (MC4R) pathway. Rhythm is advancing a portfolio of treatment options to transform the lives of patients and families affected by these debilitating conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:05
Regulatory News Service
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
English 126.1 KB

Automate Your Workflow. Get a real-time feed of all RHYTHM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RHYTHM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RHYTHM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America
PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America
PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany
PA8

Talk to a Data Expert

Have a question? We'll get back to you promptly.